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The current model for HIV-1 envelope–coreceptor interaction depicts the V3 stem and bridging sheet binding to the CCR5 N-terminus while
the V3 crown interacts with the second extracellular loop, which is the coreceptor domain that appears to be relatively more important for fusion
and infection. Our prediction based on this model is that mutations in the V3 crown might consequently have more effects on cell–cell fusion and
virus entry than mutations introduced in the V3 stem and C4 region. We performed alanine-scanning of the V3 loop and selected C4 residues in
the JRFL envelope and tested the capacity of the resulting mutants for CCR5 binding, cell–cell fusion, and virus infection. Our cross comparison
analysis revealed that residues in C4 and in both the V3 stem and crown were important for CCR5 binding of gp120 subunits. Contrary to our
prediction, mutations in the V3 crown had less effect on membrane fusion than mutations in the V3 stem. The V3 stem thus appears to be the most
important region for CCR5 utilization since it affected both coreceptor binding and subsequent fusion and viral entry. Our data raises the
possibility that some residues in the V3 crown and in C4 may play distinct roles in the binding and fusion steps of envelope–coreceptor
interaction.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1 envelope; V3 loop; Bridging sheet; CCR5 coreceptorIntroduction
Entry of human immunodeficiency virus type 1 (HIV-1) into
target cells generally requires sequential interaction between the
virus envelope glycoprotein gp120, the primary receptor CD4,
and a seven-transmembrane chemokine coreceptor. HIV-1
gp120 first binds to CD4 and undergoes conformational
changes that allow the envelope protein to interact with
chemokine coreceptors, mainly CCR5 or CXCR4 (Trkola et
al., 1996; Wu et al., 1996). Binding of the coreceptor then
triggers additional conformational changes in gp41, leading to
fusion of virus and cell membranes and subsequent viral entry
(Weiss, 2003).
The current model for coreceptor interaction based on HIV-1
subtype B is one in which the C4 and the V3 stem bind to the⁎ Corresponding author. Fax: +1 617 739 8348.
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doi:10.1016/j.virol.2006.10.019sulfated N-terminus (Nt) of CCR5 while the V3 crown interacts
with other parts of CCR5, mainly the second extracellular loop
(ECL). The features of gp120 that are important for CCR5
interaction have been defined primarily by crystal structures of
CD4-bound gp120 core with and without an intact V3 loop
(Chen et al., 2005; Huang et al., 2005; Kwong et al., 1998) and
mutagenesis involving the direct binding of monomeric gp120–
CD4 complexes to CCR5-expressing cells or to CCR5-derived
sulfopeptides (Cormier and Dragic, 2002; Cormier et al., 2001;
Rizzuto and Sodroski, 2000; Rizzuto et al., 1998).
Studies based solely on monomeric gp120 binding assays are
not sufficient to provide a comprehensive analysis of functional
gp120–CCR5 interaction. In fact, three different mutations in
the coreceptor binding domains have been reported to yield a
discordance between high affinity binding of gp120 and the
ability of the envelope to mediate cell–cell fusion and sub-
sequent viral entry (Hu et al., 2005; Hu et al., 2000; Reeves
et al., 2004). A P438A mutation in the C4 region, a D324A
Fig. 1. (A) Schematic drawing of the proviral clones used in this study. The open
rectangle represents sequences from the subtype B molecular clone HXB2RU3.
The gray rectangle in ConB represents the consensus V3 sequence of HIV-1
subtype B NSI viruses in the HXB2RU3 backbone. The filled rectangle in
HXB2-JRFL represents the SalI–BamHI env fragment (positions 5789 to 8451)
derived from the R5 subtype B strain JRFL. The EspI (8840) site used in the
cloning procedures is also indicated. (B) V3 sequences of the proviral clones,
based on the JRFL numbering. Stem (positions 297–305 and 321–329) and
crown (positions 306–320) regions are indicated. Naturally occurring alanines
in the V3 of HXB2-JRFL that were mutated to glycine are indicated in bold-
face. (C) Coreceptor utilization by the proviral clones as measured by p24 levels
in virus-infected cultures at day 7. The results represent the means and standard
deviations (S.D.) of data from three independent experiments.
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all disrupted CCR5 binding, but did not alter the usage of CCR5
in fusion and infection experiments compared to wild-type (WT)
envelope (Hu et al., 2005; Hu et al., 2000; Reeves et al., 2004).
Whether this observed phenotype is limited to just these three
residues or whether it is a more general phenomena has not been
addressed. Furthermore, it has been shown that CCR5 structures
that support binding and fusion map to overlapping but distinct
regions on the coreceptor, with the Nt of CCR5 more important
for binding while the ECLs are more important for fusion and
infection (Doranz et al., 1997). In light of this, it is conceivable
that different regions of the V3 loop and the C4 domainmay play
overlapping but distinct roles in the binding and fusion steps of
gp120 interaction with CCR5 as well.
Here, we present the first systematic cross-comparison study
of the role of individual V3 and C4 residues in CCR5 binding
and functional consequences on cell–cell fusion and viral entry.
We sought to test the hypothesis that mutations introduced to
residues in the V3 crown have more effect on cell–cell fusion
than mutations in the V3 stem and C4, despite all of these
regions contributing to CCR5 binding. Our analysis indicated
that binding of monomeric gp120 to CCR5 is susceptible to
changes in all three regions: C4 and both the V3 stem and
crown. However, contrary to our prediction, envelope-mediated
cell–cell fusion is notably affected by only specific substitutions
in the V3 stem, rather than the V3 crown.
Results
CCR5 utilization by a chimeric HIV-1 subtype B molecular
clone
We focused our analysis on the HIV-1 subtype B R5 isolate
JRFL to maintain consistency with previous studies (Cormier
and Dragic, 2002; Cormier et al., 2001). An HIV-1 chimeric
provirus containing the JRFL envelope in the genetic back-
ground of the X4 infectious molecular clone HXB2-RU3 was
the starting point for our mutagenic studies (Fig. 1A). The
ability of this chimeric construct, designated HXB2-JRFL, to
use CCR5 as an entry coreceptor was demonstrated in infection
assays using the cell lines U87-CD4-CCR5 and U87-CD4-
CXCR4, which stably express CD4/CCR5 and CD4/CXCR4,
respectively. Equivalent amounts of viruses were used to infect
the target cells, and p24 levels in the infected culture
supernatants were determined 7 days post-infection. In this
experiment, Con B, a previously described molecular clone that
contains the consensus V3 sequence of HIV-1 subtype B non-
syncitium inducing viruses in the background of HXB2-RU3
and uses CCR5 as its entry coreceptor (Trujillo et al., 1996),
served as the positive control, while HXB2-RU3 was included
as a negative control. As shown in Fig. 1C, ConB replicated to a
much higher level in CCR5-positive cells, while HXB2-RU3
replicated efficiently only in CXCR4-positive cells. The chi-
meric virus HXB2-JRFL infected only cells expressing CCR5,
which confirmed previous observations that the envelope
protein contains important determinants of coreceptor utiliza-
tion, and that replacing the V3 region of an X4 virus with thatfrom an R5 isolate is sufficient to confer coreceptor switching
(Wang et al., 1998). The HXB2-JRFL chimeric provirus was
subsequently used in this study as the parental clone to generate
gp120 mutants for further analysis.
Construction of HXB2-JRFL envelope mutants
To generate a panel of envelope mutants, alanine-scanning
mutagenesis of the entire V3 loop and selected C4 residues in
the HXB2-JRFL provirus was conducted. A total of 33 V3
mutants were made by introducing alanine substitutions to each
V3 residue from positions 297 to 329, with the two naturally
occurring alanines at positions 314 and 328 replaced with
glycine (Fig. 1B). Alanine was chosen as a substituent because
its small nonpolar methylene side chain is less likely to impose
severe constraints on gp120 and contributes little to protein–
protein interactions. In this study, we subdivided the V3 loop
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(2002) (Fig. 1B). Therefore, a total of 18 V3 stem mutations
(positions 297–305 and 321–229) and 15 V3 crown mutations
(positions 306–320) were generated. Five C4 mutants were also
constructed in a similar fashion at positions 420, 421, 422, 438
and 441. These mutant proviruses were used for the cell–cell
fusion and virus infection assays. Soluble gp120 expression
vectors derived from these envelope mutants containing
corresponding V3 and C4 substitutions were also constructed
for subsequent use in the CCR5 binding assay.
Effects of mutations on cell–cell fusion
In order to determine gp120 elements that are important for
CCR5-dependent membrane fusion, we quantitatively assessed
the ability of the mutant envelope glycoproteins to fuse with
U87-CD4-CCR5 cells using a sensitive reporter gene activation
assay (Nussbaum et al., 1994). β-Gal activity produced by the
mutant envelope clones was compared with that of the WT,
HXB2-JRFL, to score for the relative efficiency in mediating
cell–cell fusion. As shown in Fig. 2, all the V3 mutations that
markedly reduced fusogenic activity were located in the V3
stem. Alanine substitutions of six amino acids (R298A, T303A,
I321A, G323A, D324A, and R326A) in the N- and C-terminal
ends of the V3 loop reduced the ability of the envelope to
mediate fusion by more than 50% (mean plus one standard
deviation below 50% compared to WT). Three additional
mutations (N301A, R304A, and I322A) in the V3 stem also
decreased fusion by approximately 50%. In contrast, all
substitutions in the V3 crown allowed the envelope to maintain
fusogenic activity with moderate to high efficacy (60–100% of
WT). Out of the five highly conserved C4 residues that were
previously implicated in CCR5 binding (Rizzuto and Sodroski,
2000), only the I420A mutation reduced fusion by more than
50%. It is noted, however, that P438A decreased the ability of
the envelope to fuse by about 50%, and a moderate reduction
was also observed for K421A. Taken together, these data
suggest that gp120 residues in the V3 stem are the most crucial
for mediating cell–cell fusion, although C4 residues can also
modulate fusogenic activity.Fig. 2. Effect of V3 and C4 mutations on CCR5-dependent cell–cell fusion as measur
of that seen with the wild-type (WT) clone, HXB2-JRFL. White bars indicate values (
that are 50%. Data shown represent the means and standard deviations of data fromEffects of mutations on CD4 binding
It is conceivable that mutations in V3 andC4 can affect gp120
interaction with CCR5 indirectly. Since binding of gp120 to
CD4 is often a prerequisite step to CCR5 interaction, we wanted
to verify that introducing V3 and C4 mutations in gp120 did not
affect CD4 binding. ELISA was used to assay the binding of
gp120 to soluble CD4 (sCD4) for the 12 mutants that reduced
cell–cell fusion by approximately 50% or more. As shown in
Fig. 3A, all V3 mutants retained the ability to bind sCD4
efficiently (80–100% of WT), which is in agreement with
previous reports that V3 residues are not involved in CD4
binding (Wyatt et al., 1993). The I420A mutation in the C4
region, however, reduced sCD4 binding by more than two-fold
(44% of WT), suggesting that poor CD4 binding may partly
account for the observed decrease in fusion by this mutant clone.
Effects of mutations on expression, processing, and virion
incorporation
Since gp120 expression and virion incorporation can affect
the ability of the envelope to interact with CCR5, we wanted to
verify that the introduced alanine substitutions did not cause
drastic changes in these gp120 properties. Fig. 3B shows a
representative Western blot of viral lysates for the V3 and C4
mutants that reduced cell–cell fusion by approximately 50% or
more. We note that mutations N301A and T303A abolish the
known canonical N-linked glycosylation site (NXT), which
could account for the slight shift in electrophoretic mobility of
gp120. To measure the amount of envelope glycoproteins in the
viral lysates, the ratios of gp120 to p24 were determined by
densitometry. Comparable ratios observed between the WT and
defective mutants indicate similar levels of gp120 expression
and virion incorporation. In addition, we examined the viral
lysates of other mutants that retained fusogenic activity (data
not shown) and found a similar range of gp120 to p24 ratios
for the non-defective and defective envelopes. Taken together,
we saw no evidence that gp120 expression and virion
incorporation can account for the observed decrease in CCR5
usage by these mutant clones.ed by a reporter gene activation assay. β-Gal activity is expressed as a percentage
mean plus one standard deviation) less than 50%. Gray bars indicate mean values
at least three independent experiments.
Fig. 4. Effect of V3 and C4 mutations on CCR5 binding of soluble gp120–CD4 comp
WT. White bars indicate values (mean plus one standard deviation) less than 50%. Gr
the means and standard deviations of data from at least three independent experime
Fig. 3. (A) Effect on gp120–sCD4 binding, as measured by ELISA, for V3 and
C4 mutations that were found to reduce cell–cell fusion by approximately 2-fold
or more. The gray bar indicates a mean value less than 50% of WT. Data shown
represent the means and S.D. of data from three independent experiments. (B) A
representative Western blot of envelope proteins in viral lysates for V3 and C4
mutants that decreased CCR5-dependent cell fusion by approximately 2-fold or
more. Pooled sera from individuals infected with HIV-1 subtype B were used to
detect the expression of envelope proteins. The positions of the gp120 and p24
bands are labeled.
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In order to identify gp120 elements that are important for
CCR5 binding, soluble gp120 subunits containing V3 or C4
mutations were generated using expression vectors, and their
ability to bind to cell surface CCR5 was determined. We
employed a recently described quantitative cell-based ELISA
method (Zhao et al., 2004), which measures the binding of
soluble gp120–sCD4 complexes to Cf2th cells that express high
levels of CCR5. As shown in Fig. 4, alanine substitutions of
residues in both the V3 and C4 domains markedly reduced the
ability of soluble gp120–sCD4 complexes to bind to CCR5-
expressing cells. Eleven mutations located in the V3 stem
decreased CCR5 binding by more than 50% of WT, reinforcing
the role of the V3 stem in CCR5 usage. Although V3 crown
residues were not critical in mediating cell–cell fusion, seven
mutations in the V3 crown also reduced relative CCR5 binding
levels by 50% or more. In addition, five substitutions in the V3
loop (N300A, A314G, T317A, E320A, and Q327A) were found
to drastically increase CCR5 binding relative to the WT
glycoprotein (223%, 149%, 415%, 444%, and 268%, respec-
tively). In binding experiments, the role of the C4 domain in
CCR5 interaction was more pronounced, as all five C4
mutations resulted in more than an 80% reduction in CCR5
binding by monomeric gp120 subunits. Taken together, these
data indicate that binding of gp120 to CCR5 requires residues in
both the V3 stem and crown, and is dictated by some highly
conserved residues in the C4 region.
Effects of mutations on virus infection
Virus infection requires the successful completion of core-
ceptor binding and membrane fusion. To determine the effects
of gp120 V3 and C4 mutations on CCR5-dependent HIV-1
infection, U87-CD4-CCR5 target cells were infected with virus
and p24 levels were measured 7 days post-infection. As shown
in Fig. 5, V3 mutations that markedly reduced p24 levels bylexes, as measured by cell-based ELISA. Values are expressed as a percentage of
ay bars indicate mean values that are approximately 50%. Data shown represent
nts, with each experiment carried out in duplicate.
Fig. 5. Effect of V3 and C4 mutations on virus infection, as measured by p24 levels in virus-infected cultures at day 7. White bars indicate values (mean plus one
standard deviation) less than 50%. Gray bars indicate mean values that are approximately 50%. Data shown represent the means and standard deviations of data from at
least two independent experiments, with each experiment carried out in duplicate.
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C-terminal ends of the V3 loop, although we note that the
N307A and E320A mutations fall right at the junction between
the stem and the crown. The R313A substitution in the crown
that occurs right next to the GPG crest of the V3 loop also
decreased infection levels by more than 50%, although the
reduction was not quite as pronounced as some of the other V3
stem mutations. We also observed that only two (I420A and
K421A) C4 mutations resulted in poor viral replication, as
measured by more than a 50% decrease in p24 levels relative
to WT.
Comparisons of cell–cell fusion, CCR5 binding, and virus
infection assays
To determine whether the CCR5 binding assay or the cell–
cell fusion assay is a better indicator of CCR5 utilization, we
examined whether the ability of monomeric gp120 to bind to
CCR5 or the ability of the envelope glycoprotein to mediate
cell–cell fusion correlated better with virus infection in CCR5-
expressing cells. Upon comparing relative binding, fusion, and
infection levels, we identified two groups of mutants with
interesting phenotypes. The first group contained mutants that
are deficient in CCR5 binding but are able to mediate fusion and
infection with moderate to high efficiency. These included
mainly V3 crown and C4 mutants, with the most pronounced
being the V3 mutants P311A, G312A, Y316A, and H329A and
the C4 mutants Q422A and G441A. The second group
consisted of mutants that display dramatically enhanced binding
to CCR5 with no corresponding increases in fusion and
infection levels. Five V3 mutants (N300A, A314G, T317A,
E320A, and Q327A) consistently showed increased binding to
CCR5, between 2 and 4 times that of WT. Overall, using the
Spearman rank correlation method with Bonferroni-adjusted
significance level, we found a positive correlation between
CCR5 binding and cell–cell fusion (rs=0.7350, p<0.0001).
However, our data indicates that CCR5 binding by monomeric
gp120 does not always predict CCR5 usage by gp120 when it is
presented in its more native state, such as that used in the
fusion and virus infection assays. In addition, we found a highercorrelation between relative infection and fusion (rs=0.5372,
p=0.0013) than between relative infection and CCR5 binding
(rs=0.4194, p=0.0236).
Discussion
In this study, we systematically compared the involvement
of V3 stem, crown, and C4 residues in the binding and fusion
steps of gp120–CCR5 interaction using the subtype B JRFL
envelope as a model system. The premise of this study was
that CCR5 structures that support binding and fusion have
been mapped to overlapping but distinct regions, with the Nt
more important for binding and the ECLs more critical for
fusion and infection (Doranz et al., 1997). It follows that
gp120 domains that support binding and fusion may involve
overlapping but distinct regions as well. Given that the current
model for gp120–CCR5 interaction depicts the V3 stem and
C4 binding to the CCR5 Nt while the V3 crown interacts with
the ECL2, we hypothesized that mutations in the V3 crown
could have more impact on fusion and viral entry than those in
the V3 stem and C4 region. We conducted alanine-scanning of
the V3 loop and five highly conserved C4 residues in the JRFL
envelope and compared the effects of these substitutions on
cell–cell fusion, CCR5 binding, and virus infection levels. Our
results provide strong evidence, at least in the strain analyzed,
that CCR5 binding does not always predict functional CCR5
usage by gp120 and indicate that mutating some V3 crown and
C4 residues can have differential effects on the binding and
fusion steps of gp120–CCR5 interaction. Contrary to our
prediction, we found that mutations in the V3 crown had a
large impact on gp120–CCR5 binding but had relatively little
or no impact on fusion and virus infectivity. Instead, eight
substitutions in highly conserved V3 stem residues reduced
both CCR5 binding and subsequent fusion and viral entry by
more than 50%.
It should be noted that using the envelope glycoprotein of
ConB, Wang et al. (1999) identified three residues in the V3
crown that were also important for virus infection via CCR5.
However, since mutants of ConB were not studied for cell–
cell fusion or CCR5 binding, it is unclear whether the V3
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post-entry step in viral replication. In fact, we also identified
three mutations in the V3 crown that reduced virus infection
by more than 50% in this study, but none of these mutants
significantly altered fusogenicity. We note that two of these
three mutations (I307A and R313A) are identical to those
identified by Wang et al. (1999). Since these mutants were
able to mediate cell–cell fusion but replicated poorly in
CCR5-expressing cells, the possibility that the V3 mutations
may affect some early post-entry step in viral replication
needs to be considered.
In a previous study by Cormier et al. (2001), 16 out of 33
V3 loop residues were studied for their involvement in
binding to cell-surface CCR5. In this study, we systematically
analyzed all V3 residues in the stem and crown and looked at
their effects on CCR5 binding as well as their functional
consequences on cell–cell fusion and viral entry. We note that
our results are largely in agreement with Cormier et al. (2001)
among the residues that we both analyzed, with the exception
of two point mutations (G310A and F315A). In the study by
Cormier et al. (2001), both mutants decreased CCR5 binding
by more than 50%, but these mutations were not as critical in
our study. One possible explanation for this discrepancy could
be differences in the sensitivities of the binding assays used,
which involved different forms of CD4 and different cell
lines that may express different cell-surface concentrations of
CCR5.
Our finding provides functional evidence that CCR5
interaction by the V3 stem is not limited to just a few
structurally defined “base” residues (positions 297–299) that
form an integral portion of the gp120 core, as has been
suggested by the V3 crystal structure of Huang et al. (2005).
Furthermore, the crystal structure appears to suggest that the
base of the V3 loop lies in close proximity to the bridging sheet,
which encompasses the five C4 mutants analyzed in this study.
Our data, however, raises the possibility that the structurally
defined V3 “base” and C4 region may not form a unified
functional entity given their different effects on binding and
fusion.
Disrupting the gp120 V3 or C4 regions can lead to
differences in coreceptor binding and cell–cell fusion by
affecting the molecular anatomy of CCR5 utilization. Mutations
that limit the functional interaction of gp120 to only one CCR5
domain may weaken the affinity of gp120 to CCR5, which can
be below the threshold for detectable binding by monomeric
gp120 but is sufficient for fusion to occur. Fusion assays employ
oligomeric envelope proteins, so a change in affinity of indi-
vidual gp120 subunits may be compensated by the overall
avidity of the trimer to CCR5. In support of this, two V3 loop
mutations that did not alter CCR5 usage in fusion and
infection experiments were reported to reduce coreceptor
binding by two-fold and affected the molecular anatomy of
CCR5 utilization (Hu et al., 2005; Hu et al., 2000). From our
study, it appears that there are other residues mostly in the V3
crown and C4 region that could similarly affect gp120
utilization of different CCR5 domains. To lend further support
to this interpretation, future studies that examine the bindingand fusion of our gp120 mutants to cells expressing CCR5
coreceptor chimeras are needed.
Alternatively, V3 or C4 mutations may enhance the effi-
ciency or kinetics with which CCR5 binding triggers conforma-
tional changes in gp120 that lead to membrane fusion, thus
allowing lower affinity envelopes to effectively utilize CCR5 for
fusion events. Reeves et al. (2004) reported one C4mutation that
highly disrupted gp120–CCR5 binding but not fusion and
infection. This mutant displayed increased sensitivity to the
binding inhibitor TAK-779 but lower sensitivity to the fusion
inhibitor T-20, which suggested lower gp120–CCR5 affinity but
increased efficiency of membrane fusion. Similarly, some V3
mutations have also been shown to enhance fusogenicity,
thereby decreasing viral sensitivities to T-20 and enabling the
virus to use low affinity CCR5 mutants (Platt et al., 2005a; Platt
et al., 2005b). In light of these findings, future studies that test
our envelope mutants for sensitivity to the inhibitors TAK-779
and T-20 may help further clarify the mechanism of action of the
introduced substitutions.
We also noted that five mutations in the V3 stem and
crown consistently resulted in dramatically enhanced binding
with no corresponding increases in fusion and infection levels.
Only one of these five V3 substitutions (E320A) has pre-
viously been studied, and this mutation was indeed shown to
increase CCR5 binding (Cormier et al., 2001). It is possible
that these V3 mutations may alter the conformation of gp120
such that it becomes more accessible to CCR5 and enhances
coreceptor affinity. These residues may form close contacts
with CCR5, or they may form bonds internally within gp120
that stabilize the topology of the V3 crown and stem regions.
It should be emphasized, however, that these mutations appear
to affect the affinity of monomeric more than trimeric envelope,
since we see no corresponding increases in fusion or infection
levels.
The cascade of early events in the viral life cycle starts with a
virus binding to the appropriate receptors on target cells, leading
to efficient membrane fusion events, viral entry, and subse-
quently, productive infection. In this study, new evidence is
provided to support the notion that CCR5 binding assays using
monomeric gp120 do not always predict CCR5 utilization by
gp120 when it is presented in its trimeric form. Furthermore, we
show that infection levels correlated higher with fusogenicity
than with CCR5 binding, suggesting that the cell–cell fusion
assay is more predictive of CCR5 usage and viral entry than the
monomeric gp120 binding assay.
We recognize that HIV-1 is not a genetically homogenous
family of virus and the question as to what extent our finding
will be shared by other HIV-1 requires further study. It is noted
that the results on cell fusion and virus infectivity are actually
consistent with our previous work using a subtype C envelope
(Suphaphiphat et al., 2003), thus reinforcing the relatively more
important role of the V3 stem compared to the V3 crown and C4
region in overall CCR5 usage even with a genetically divergent
HIV-1 strain. However, future studies that look at other HIV-1
isolates and subtypes will help determine how general these
findings are to other envelopes. Our data does emphasize the
importance of analyzing both coreceptor binding and cell–cell
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distinct roles in the binding and fusion steps of gp120–CCR5
interaction. The direct binding assay alone is not sufficiently
robust to fully delineate HIV envelope–coreceptor interactions
during viral entry.
Materials and methods
Cells
Human kidney 293 cells and African green monkey CV-1
cells were maintained at 37 °C in DMEM supplemented with
10% fetal bovine serum and 1% penicillin–streptomycin
(DMEM/FBS/PS). Human glioma cell lines, U87-CD4-CCR5
and U87-CD4-CXCR4, and the canine thymocyte cell line,
Cf2th/synCCR5, were obtained from the NIH AIDS Research
and Reference Reagent Program (NIH, Bethesda, MD). U87
cells were cultured in DMEM/FBS/PS plus 1 μg/ml puromycin
and 300 μg/ml genecitin (Sigma, St. Louis, MO). Cf2Th/
synCCR5 cells were maintained in DMEM/FBS/PS with
3 μg/ml puromycin, 500 μg/ml genecitin, and 500 μg/ml
ZeocinTM (Invitrogen, Carlsbad, CA).
Construction of chimeric and mutant viruses
The HIV-1 subtype B molecular clone HXB2-RU3 has
previously been described (Trujillo et al., 1996). HXB2-JRFL/
d2EGFP, a chimeric molecular clone containing the JRFL
envelope that contains an artificially inserted BamHI site in
the env region and tagged with d2EGFP, was contributed by Z.
Matsuda (NIH). The 2.6-kb SalI–BamHI envelope fragment of
HXB2-JRFL/d2EGFP was used to replace the corresponding
env region of HXB2-RU3 to generate an HXB2-JRFL provirus
that does not contain the GFP tag. To generate JRFL envelope
mutant clones, the SalI–EspI envelope fragment of HXB2-
JRFL was cloned into the PGEM11 vector (Promega, Madison,
WI) to create the subclone PGEM-JRFL. Site-directed
mutagenesis by overlap extension PCR (Ho et al., 1989)
was used to introduce single alanine substitutions to each of
the V3 residues, as well as to five C4 residues. The SalI–
EspI fragment of PGEM-JRFL containing the directed
mutation was cloned back into HXB2-JRFL to generate the
full-length proviral clones. All mutations were verified by
DNA sequencing.
Construction of soluble gp120
The 3.0-kb SalI–EspI envelope fragment of PGEM-JRFL
was cloned into a p303TD expression vector (Invitrogen) to
generate TD-JRFL. Using TD-JRFL as template, a stop codon
(TAA) was inserted at the end of gp120 by overlap extension
PCR to generate the soluble JRFL gp120 expression vector,
sTD-JRFL. Soluble C4 mutant gp120 expression vectors were
constructed in a similar fashion, using PGEM-JRFL clones
containing the directed C4 mutation. To create soluble V3
mutant gp120 expression vectors, the SalI–Bsu36I fragment of
PGEM-JRFL clones containing the desired V3 mutation wasdirectly cloned into sTD-JRFL. To generate soluble gp120, 5 μg
of sTD-JRFL and mutants were transfected into 8×105 293
cells using the Superfect Transfection Reagent (Qiagen,
Hidden, Germany) and cell-free supernatants were collected
72 h after transfection, and frozen at −80 °C until used.
Virus infection in U87-CD4-CCR5 cells
Ten micrograms of proviral DNA were transfected into
1.5×106 293 cells using Superfect. Cell-free supernatants were
collected 72 h after transfection, passed through 0.45 μm filters
(Millipore Corporation, Bedford, MA), and frozen at −80 °C
until used. The p24 concentration was determined by the HIV-1
p24 ELISA kit (NEN Life Science Products, Boston, MA). To
monitor viral replication, equal amounts of viruses, stan-
dardized by 10 ng of p24, were used to infect 1×105 U87-
CD4-CCR5 or U87-CD4-CXCR4 cells in a 24-well plate.
Culture supernatants were assayed by p24 ELISA on day 7
post-infection.
β -Galactosidase reporter gene activation assay to measure cell
fusion
Fusion was analyzed by modification of a previously des-
cribed reporter gene activation assay (Nussbaum et al., 1994).
8×104 293 cells on 96-well microtiter plates were transfected
with 0.5 μg proviral DNA using Superfect. After 48 h, the cells
were infected with the recombinant vaccinia-virus vCB21R-
lacZ (MOI 10; NIH AIDS Research and Reference Reagent
Program) containing the Escherichia coli lacZ gene linked to a
bacteriophage T7 promoter. A second population of cells, U87-
CD4-CCR5, was infected with the recombinant vaccinia-virus
vTF7-3 (MOI 10; NIH AIDS Research and Reference Reagent
Program), which expresses T7 RNA polymerase under the
control of the natural P7.5 early–late vaccinia virus promoter.
After 1.5 h, the cells were washed with phosphate-buffered
saline (PBS) and incubated overnight. U87-CD4-CCR5 cells
were scraped, and 8×104 cells were added to the 293 cells.
Fusion was allowed to proceed for 6 h, after which cells were
lysed by the addition of Reporter Lysis Buffer (Promega). β-Gal
activity in cell lysates was assayed using the β-Gal Assay Kit
(Invitrogen). The value for cell fusion (based on β-Gal activity)
was calculated with the formula: cell fusion=(Mutantfusion÷
WTfusion)×100.
Western blot analysis of cell and viral lysates
Ten micrograms of proviral DNA were transfected into
1.5×106 293 cells using Superfect. Cell and viral lysates were
prepared as described (Wang et al., 1999) and analyzed by SDS-
PAGE. A reference pooled HIV-1 subtype B positive serum
(1:400 dilution) was used for Western blot analysis.
ELISA for gp120–sCD4 binding
Soluble CD4 (sCD4) was obtained by infecting CV-1 cells
with the recombinant vaccinia virus vCB5, a sCD4-expression
189P. Suphaphiphat et al. / Virology 360 (2007) 182–190vector (MOI 40; NIH AIDS Research and Reference Reagent
Program), for 3 h. Following overnight incubation, cell-free
supernatants were collected and treated with 1% Triton-X for
30 min at 4 °C. Gp120 was generated by transfecting 293 cells
with 10 μg of proviral DNA and harvesting cell lysates 72 h
after transfection. The amount of gp120 in the cell lysates was
determined by ELISA. Sheep polyclonal antibody (Ab) D7324
to the conserved C-terminal 15 amino acids of HIV-1 gp120
(NIH AIDS Research And Reference Reagent Program) was
used as capture Ab, and pooled HIV-1 subtype B human serum
was used as detection Ab. Bound Ab was detected using
alkaline phosphatase (AP)-conjugated goat anti-human Ig and
the AMPAK system (Dako, Cambridgeshire, UK). Binding of
gp120 to sCD4 was carried out as previously described (Moore,
1990), with several modifications. Gp120 in cell lysates was
incubated in wells coated with 2 μg/ml D7324. Equal amounts
of supernatant containing sCD4 were added to the wells, and
bound sCD4 was detected using T4-4, a rabbit polyclonal Ab
against CD4 (NIH AIDS Research and Reference Reagent
Program). The concentration of sCD4 used displayed about
half-maximal binding to captured gp120. AP-conjugated goat
anti-rabbit IgG was used as secondary Ab and was detected
using the AMPAK system. A490 was monitored with a
microtiter plate absorbance reader. The value for sCD4
binding, normalized for the amount of gp120 in the cell
lysate, was calculated with the formula: sCD4 Binding=
(MutantsCD4÷WTsCD4)× (WTcell lysate ÷Mutantcell lysate)×100.
Cell-based ELISA for CCR5 binding
CCR5 binding assays were carried out as previously des-
cribed (Zhao et al., 2004), with the following modifications.
5×104 Cf2th/synCCR5 cells were seeded into 96-well plates
and cultured at 37 °C overnight. Cells were fixed with 5%
formaldehyde in 0.01 M PBS for 5 min at RT. The plates were
washed three times with PBS containing 0.05% Tween 20 and
blocked with 5% nonfat dry milk in 0.01 M PBS at 4 °C
overnight. Soluble gp120–sCD4 complexes, formed by
incubating 200 μl soluble gp120-containing supernatants with
1 μg sCD4 (Protein Sciences, Meriden, CT) for 1 h at RT with
gentle shaking, were added to each well and incubated at 37 °C
for 1 h. Bound complexes were detected using M-T441, a
mouse Ab that recognizes the D2 domain of CD4 (Ancell,
Bayport, MN), followed by AP-conjugated sheep anti-mouse
IgG as secondary antibody. The amount of soluble gp120 in the
supernatant was also determined by ELISA, as described above
for determining the amount of gp120 in cell lysates. The
amount of bound gp120–sCD4 complex, normalized for the
amount of soluble gp120 in the supernatant, was calculated
using the following formula: CCR5 Binding=(MutantCCR5÷
WTCCR5)× (WTsupernatant÷ Mutantsupernatant)×100.
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